Nephros Analyst Ratings
Benchmark Reiterates Speculative Buy on Nephros, Maintains $5 Price Target
Nephros: Buy Rating Affirmed Amid Solid Performance and Growth Prospects
Nephros Poised for Growth: A Buy Recommendation Amid Expansion and Optimized Operations
Nephros Analyst Ratings
Nephros Poised for Growth: Strong Financials and Strategic Initiatives Secure Buy Rating
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and Nephros (NEPH)
Maxim Group Sticks to Their Buy Rating for Nephros (NEPH)
Nephros (NEPH) Receives a Buy From Maxim Group
Maxim Group Sticks to Its Buy Rating for Nephros (NEPH)
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Nephros (NEPH)
Analysts Are Bullish on Top Healthcare Stocks: Sanofi (SNYNF), Nephros (NEPH)
B. Riley Securities Lowers Nephros' Price Target to $4.25 From $5.25 Ahead of Q3 Results, Lowers Estimates; Maintains Buy Rating
No Data